Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy.
OBJECTIVE
The objective of this study was to determine the gadolinium (Gd) concentration remaining in human bone tissue after administration of standard clinical doses of 2 Gd-based contrast agents: ProHance and Omniscan.


METHODS
After administration of 0.1 mmol/kg of Gd chelate to patients undergoing hip replacement surgery, bone specimens were collected and analyzed, and compared with an age-matched control population without a history of Gd chelate administration. Bone specimens were collected fresh, refrigerated, and subsequently frozen. After grinding and freeze-drying, tissue digestion was performed using Teflon bombs and concentrated nitric acid. A method for analysis of Gd in bone specimens was developed and validated using inductively coupled plasma mass spectroscopy (ICP-MS).


RESULTS
Results were compared with a previous study using a different technique for analysis of the same tissue specimens. Tissue retention was 1.77+/-0.704 microg Gd/g bone (n=9) for Omniscan and 0.477+/-0.271 microg Gd/g bone (n=10) for ProHance measured by ICP-MS. These findings confirmed results from the previous ICP-AES study.


CONCLUSIONS
Omniscan (Gd[DTPA-BMA]) left approximately 4 times (previous study 2.5 times) more Gd behind in bone than did ProHance (Gd[HP-DO3A]).
Ernst Felder Laboratories, Bracco Research USA, Princeton, New Jersey 08540, USA. Gregory.White@bru.bracco.com
Gregory W
GW
White
Wendell A
WA
Gibby
Michael F
MF
Tweedle
D019644:Arthroplasty, Replacement, Hip; D003238:Connective Tissue; D003287:Contrast Media / Q000378:metabolism / Q000493:pharmacokinetics*; D005270:Femur Head / Q000378:metabolism*; D005682:Gadolinium; D019786:Gadolinium DTPA / Q000378:metabolism / Q000493:pharmacokinetics*; D006571:Heterocyclic Compounds / Q000378:metabolism / Q000493:pharmacokinetics*; D006801:Humans; D013058:Mass Spectrometry; D009942:Organometallic Compounds / Q000378:metabolism / Q000493:pharmacokinetics*; D012044:Regression Analysis
D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; C064925:gadodiamide; D005682:Gadolinium; D019786:Gadolinium DTPA